Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Populatio | OTT
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. - Abstract - Europe PMC
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR -mutated, NSCLC HCC827 cells | Oncogenesis
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.,Cancer Science - X-MOL
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target - ScienceDirect
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Figure 6 from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer | Semantic Scholar
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications - Zorzetto - Translational Lung Cancer Research
new-molecular-drivers-in-nsclc-the-role-of-met
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
